ProKidney Corp. (PROK)
PROK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/0001193125-26-113881-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PROK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001850270 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $893K |
| Net income | -$69.0M |
| Operating income | -$165.0M |
| Net margin | -7725.2% |
| Operating margin | -18477.8% |
| Revenue growth | +1075.0% |
| Cash | $108.5M |
| Total assets | $335.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 352.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These matters raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $81.4M cash; operating cash flow -$38.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 302,381,712 (2026-11-12); 300,834,379 a year earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Atlanta, Georgia, United States | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $174K | -$35.6M | -$38.7M | $81.4M | No debt tags | $775K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $150K | -$28.4M | -$40.4M | $74.9M | No debt tags | $818K | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $226K | -$20.0M | -$41.7M | $101.9M | No debt tags | $889K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $225K | -$19.2M | -$32.5M | $108.5M | No debt tags | $893K | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $217K | -$16.5M | -$26.6M | $95.3M | No debt tags | $744K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $221K | -$16.6M | -$31.4M | $84.9M | No debt tags | $527K | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $230K | -$16.7M | -$29.6M | $97.8M | No debt tags | $306K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $76K | -$21.3M | -$24.2M | $99.1M | No debt tags | $76K | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 406 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.3% |
| 1 month | -33.4% |
| 3 months | -25.6% |
| Year to date | -53.3% |
| 1 year | -54.2% |
| From 52-week high | -59.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.14 | -2.56% | $303.6M |
| KYTX | Kyverna Therapeutics Inc. | $4.76 | -5.74% | $300.9M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| AGMB | AgomAb Therapeutics NV | $5.97 | -6.13% | $294.0M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier